Showing results (1-10 of 20) with videos related to
Sort By:
Pageof 2
Advances in Preventive Medicine|April 27, 2012
The need for continued development of ricin countermeasuresRonald B Reisler, Leonard A SmithVaccine|January 12, 2010
Immunogenicity of an inactivated Japanese encephalitis vaccine (JE-VAX) in humans over 20 years at USAMRIID: using PRNT50 as an endpoint for immunogenicityRonald B Reisler, Denise K Danner, Paul H GibbsVaccine|October 4, 2012
Immune interference in the setting of same-day administration of two similar inactivated alphavirus vaccines: eastern equine and western equine encephalitisRonald B Reisler, Paul H Gibbs, Denise K Danner, et al.Journal of Acquired Immune Deficiency Syndromes (1999)|May 21, 2005
Incidence of pancreatitis in HIV-1-infected individuals enrolled in 20 adult AIDS clinical trials group studies: lessons learnedRonald B Reisler, Robert L Murphy, Robert R Redfield, et al.Annual Review of Pharmacology and Toxicology|December 14, 2016
Will There Be a Cure for Ebola?Anthony P Cardile, Travis K Warren, Karen A Martins, et al.Journal of Acquired Immune Deficiency Syndromes (1999)|November 15, 2003
Grade 4 events are as important as AIDS events in the era of HAARTRonald B Reisler, Cong Han, William J Burman, et al.AIDS Patient Care and Stds|December 29, 2006
Immune reconstitution inflammatory syndrome presenting as sinusitis with inflammatory pseudotumor in an HIV-infected patient: a case report and review of the literatureKirk M Chan-Tack, K Savitha Chengappa, Jeffrey S Wolf, et al.Expert Review of Anti-Infective Therapy|December 7, 2017
Treatment-focused Ebola trials, supportive care and future of filovirus careMaryam Keshtkar-Jahromi, Karen A O Martins, Anthony P Cardile, et al.Journal of Acquired Immune Deficiency Syndromes (1999)|September 13, 2006
Predictors of antiretroviral-related hepatotoxicity in the adult AIDS Clinical Trial Group (1989-1999)Julie C Servoss, Douglas W Kitch, Janet W Andersen, et al.Vaccine|November 8, 2015
Safety and immunogenicity of ricin vaccine, RVEc™, in a Phase 1 clinical trialPhillip R Pittman, Ronald B Reisler, Changhong Y Lindsey, et al.Pageof 2